Oculis (NASDAQ:OCS) Given Sell (D-) Rating at Weiss Ratings

Key Points

• Oculis (NASDAQ:OCS) has been given a sell (D-) rating by Weiss Ratings, which is restating its negative outlook on the stock.
• Despite the negative rating from Weiss, analysts from other firms like Needham & Company and HC Wainwright have issued "buy" ratings with price targets ranging from $36.00 to $51.00.
• Oculis reported a quarterly earnings loss of ($0.59) EPS, missing consensus estimates, but generated revenue that exceeded analyst expectations.

Oculis (NASDAQ:OCS - Get Free Report)'s stock had its "sell (d-)" rating restated by analysts at Weiss Ratings in a note issued to investors on Saturday,Weiss Ratings reports.

Several other research firms also recently commented on OCS. Needham & Company LLC initiated coverage on shares of Oculis in a report on Wednesday, August 27th. They issued a "buy" rating and a $36.00 price objective on the stock. HC Wainwright boosted their target price on shares of Oculis from $33.00 to $36.00 and gave the company a "buy" rating in a research note on Tuesday, October 7th. Wall Street Zen cut shares of Oculis from a "hold" rating to a "sell" rating in a research note on Sunday, September 21st. Finally, Chardan Capital boosted their target price on shares of Oculis from $33.00 to $51.00 and gave the company a "buy" rating in a research note on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $41.00.

Oculis Stock Down 0.5%

OCS stock opened at $21.25 on Friday. The firm's fifty day simple moving average is $18.41 and its 200-day simple moving average is $18.39. The company has a market capitalization of $927.78 million, a P/E ratio of -7.96 and a beta of 0.29. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.55 and a quick ratio of 4.55. Oculis has a 12 month low of $14.00 and a 12 month high of $23.08.

Oculis (NASDAQ:OCS - Get Free Report) last released its quarterly earnings data on Thursday, August 21st. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.06). The business had revenue of $0.25 million during the quarter, compared to analysts' expectations of $0.14 million. Oculis had a negative net margin of 13,958.12% and a negative return on equity of 90.31%. As a group, equities research analysts forecast that Oculis will post -2.09 earnings per share for the current year.

Hedge Funds Weigh In On Oculis

Large investors have recently added to or reduced their stakes in the stock. Kestra Private Wealth Services LLC acquired a new position in Oculis during the first quarter worth $234,000. Bosun Asset Management LLC acquired a new position in Oculis during the second quarter worth $378,000. Marshall Wace LLP acquired a new position in Oculis during the second quarter worth $393,000. Geode Capital Management LLC raised its position in Oculis by 27.7% during the second quarter. Geode Capital Management LLC now owns 29,436 shares of the company's stock worth $571,000 after acquiring an additional 6,384 shares during the period. Finally, Bank of America Corp DE raised its position in Oculis by 2.2% during the second quarter. Bank of America Corp DE now owns 40,512 shares of the company's stock worth $786,000 after acquiring an additional 878 shares during the period. 22.30% of the stock is currently owned by institutional investors and hedge funds.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.